---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010377"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:29:46.841702+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025

## Summary
- Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.
- R&D expense $1.9M (down $0.2M); MG&A $1.6M (up $0.8M on legal/professional fees).
- Cash $9.1M at Mar 31, 2025 vs $5.6M at Dec 31, 2024; $6.4M from financing.
- First patients in Australian CBGM feasibility study expected Q3 2025; FDA IDE pilot study expected Q4 2025.
- First-in-human study met primary endpoint; no device-related serious adverse events.

## SEC filing metadata
- accession: 0001641172-25-010377
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/0001641172-25-010377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010377
- JSON: https://secwatch.observer/filing/0001641172-25-010377.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.